Related Experiment Video
Updated: Apr 30, 2026
Intra-lymph Node Injection of Biodegradable Polymer Particles
Published on: January 2, 2014
Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes
Laura Jeanbart1, Marie Ballester, Alexandre de Titta
1Authors' Affiliations: Ludwig Center for Cancer Research, Université de Lausanne (UNIL), Lausanne, Switzerland.
Abstract:
The sentinel or tumor-draining lymph node (tdLN) serves as a metastatic niche for many solid tumors and is altered via tumor-derived factors that support tumor progression and metastasis. tdLNs are often removed surgically, and therapeutic vaccines against tumor antigens are typically administered systemically or in non-tumor-associated sites. Although the tdLN is immune-suppressed, it is also antigen experienced through drainage of tumor-associated antigens (TAA), so we asked whether therapeutic vaccines targeting the tdLN would be more or less effective than those targeting the non-tdLN. Using LN-targeting nanoparticle (NP)-conjugate vaccines consisting of TAA-NP and CpG-NP, we compared delivery to the tdLN versus non-tdLN in two different cancer models, E.G7-OVA lymphoma (expressing the nonendogenous TAA ovalbumin) and B16-F10 melanoma. Surprisingly, despite the immune-suppressed state of the tdLN, tdLN-targeting vaccination induced substantially stronger cytotoxic CD8+ T-cell responses, both locally and systemically, than non-tdLN-targeting vaccination, leading to enhanced tumor regression and host survival. This improved tumor regression correlated with a shift in the tumor-infiltrating leukocyte repertoire toward a less suppressive and more immunogenic balance. Nanoparticle coupling of adjuvant and antigen was required for effective tdLN targeting, as nanoparticle coupling dramatically increased the delivery of antigen and adjuvant to LN-resident antigen-presenting cells, thereby increasing therapeutic efficacy. This work highlights the tdLN as a target for cancer immunotherapy and shows how its antigen-experienced but immune-suppressed state can be reprogrammed with a targeted vaccine yielding antitumor immunity.
Insights
Targeting the tumor-draining lymph node (tdLN) with nanoparticle vaccines surprisingly enhances anti-tumor immunity. This approach reprograms the immune-suppressed tdLN, leading to stronger T-cell responses, tumor regression, and improved survival.
Area of Science:
- Immunology
- Oncology
- Nanotechnology
Background:
- The tumor-draining lymph node (tdLN) is a critical site for cancer metastasis and immune responses.
- Current cancer vaccines are often administered systemically or at non-tdLN sites, potentially missing a key immune niche.
- The tdLN is paradoxically immune-suppressed yet antigen-experienced, presenting a unique therapeutic challenge.
Purpose of the Study:
- To investigate the efficacy of targeting the tdLN with nanoparticle (NP)-conjugate vaccines compared to non-tdLN vaccination.
- To determine if the immune-suppressed state of the tdLN can be overcome to generate anti-tumor immunity.
- To explore the role of nanoparticle delivery in enhancing vaccine efficacy within the tdLN.
Main Methods:
- Development of LN-targeting nanoparticle (NP)-conjugate vaccines comprising tumor-associated antigen (TAA)-NP and CpG-NP.
- Comparison of tdLN-targeting versus non-tdLN-targeting vaccination strategies in E.G7-OVA lymphoma and B16-F10 melanoma models.
- Analysis of cytotoxic CD8+ T-cell responses, tumor infiltration, and host survival.
Main Results:
- tdLN-targeting vaccination induced significantly stronger cytotoxic CD8+ T-cell responses compared to non-tdLN vaccination.
- Enhanced tumor regression and host survival were observed in the tdLN-targeting group.
- Nanoparticle coupling of antigen and adjuvant was essential for effective tdLN delivery and therapeutic efficacy.
- A shift towards a less suppressive and more immunogenic leukocyte profile within tumors was correlated with improved outcomes.
Conclusions:
- The tdLN represents a viable and effective target for cancer immunotherapy.
- Targeted nanoparticle vaccines can reprogram the immune-suppressed tdLN to elicit potent anti-tumor immunity.
- This strategy offers a promising approach to enhance cancer vaccine efficacy and overcome tumor-induced immune suppression.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Modified-Release Drug Delivery Systems: Site-Targeted